Amgen Launches Program To Further Advance Basic Biology Research

Amgen today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology.

PRESS RELEASE

THOUSAND OAKS, Calif., May 28, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology, as well as deepen relationships with academic institutions. This catalog and its associated materials are called the Amgen Biology-Enabling Resource (AmBER).

AmBER is comprised of more than 1,000 elements and includes small molecules, peptides, antibodies and recombinant proteins, engineered cell lines, and genetically-engineered mice. These are tools created to support discovery activities throughout Amgen's history and have been extensively validated in most cases.

"We see AmBER as an important contribution in our effort to connect with the academic community and to help advance scientific discovery," said Alexander Kamb, Ph.D., senior vice president of Discovery Research at Amgen. "AmBER will allow Amgen to further expand relationships around innovative biology and medicine and enhance research literature quality by providing qualified materials."

Amgen scientists and staff assembled these materials and have organized pertinent information into a searchable catalog. This catalog is available to designated institutions. Amgen will provide the materials on request as a donation to the cause of basic science--with no claim to ownership of intellectual property to discoveries that may ensue. As specific materials are depleted, Amgen anticipates others will be added so that AmBER continues as an evolving resource for academics.

For inquiries about the AmBER project, please email amber.research@amgen.com.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.